4.8 Review

Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials

期刊

NATURE REVIEWS DRUG DISCOVERY
卷 20, 期 8, 页码 611-628

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41573-021-00210-8

关键词

-

资金

  1. MRC HGU Programme [MC_UU_00007/9]
  2. European Research Council [ZF-MEL-CHEMBIO-648489]
  3. Melanoma Research Alliance [687306]
  4. Cancer Biology [R01 CA103846]
  5. NIH Melanoma PPG [P01CA63222]
  6. Melanoma Research Alliance
  7. Starr Cancer Consortium grant
  8. NIH grants [R01CA211734, R01CA154923, R01CA215118, RO1CA226926, R24OD016761]
  9. MGH Research Scholar Award
  10. MRC [MC_UU_00007/9] Funding Source: UKRI

向作者/读者索取更多资源

Zebrafish have become a valuable tool in drug discovery, particularly in screening, disease modeling, and toxicity assays. Recent advances in gene modification technologies and xenografts have enabled personalized treatments and rapid drug discovery platforms using zebrafish models. The unique features of zebrafish make them an important model organism for maximizing potential in medical discoveries.
Numerous drug treatments that have recently entered the clinic or clinical trials have their genesis in zebrafish. Zebrafish are well established for their contribution to developmental biology and have now emerged as a powerful preclinical model for human disease, as their disease characteristics, aetiology and progression, and molecular mechanisms are clinically relevant and highly conserved. Zebrafish respond to small molecules and drug treatments at physiologically relevant dose ranges and, when combined with cell-specific or tissue-specific reporters and gene editing technologies, drug activity can be studied at single-cell resolution within the complexity of a whole animal, across tissues and over an extended timescale. These features enable high-throughput and high-content phenotypic drug screening, repurposing of available drugs for personalized and compassionate use, and even the development of new drug classes. Often, drugs and drug leads explored in zebrafish have an inter-organ mechanism of action and would otherwise not be identified through targeted screening approaches. Here, we discuss how zebrafish is an important model for drug discovery, the process of how these discoveries emerge and future opportunities for maximizing zebrafish potential in medical discoveries. Zebrafish are useful model organisms for drug discovery, particularly in screening, disease modelling and toxicity assays. Here, Patton, Zon and Langenau discuss key recent successes in which zebrafish models have had key roles. Advances in gene modification technologies have enabled individual mutations to be recapitulated in zebrafish, leading to individualized treatments. Zebrafish xenografts as cancer models could also lead to rapid, personalized platforms for drug discovery.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据